Mahmoud AN, et al. - The efficacy and safety of second-generation drug-eluting stents (DES; eg, everolimus and zotarolimus), relative to bare-metal stents (BMS), was assessed in this updated systematic review and meta-analysis of relevant randomized clinical trials (RCTs). Although all-cause mortality appeared similar between groups, second-generation DES vs BMS appeared to be related to a lower incidence of major adverse cardiac events (MACE), primarily driven by lower rates of target-lesion revascularization, myocardial infarction (MI), and stent thrombosis.